Ertugliflozin 5 mg

DRUG12 trials

Sponsors

Merck Sharp & Dohme LLC, University Hospitals Cleveland Medical Center, Medical University of Graz

Conditions

Cardiac Resynchronization TherapyDiabetes Mellitus, Type 2Heart Failure With Mid Range Ejection FractionHeart Failure With Reduced Ejection FractionHeart Failure, DiastolicHypertensionImplantable Cardioverter-DefibrillatorsType 2 Diabetes Mellitus

Phase 2

Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

CompletedNCT01059825

Merck Sharp & Dohme LLCDiabetes Mellitus, Type 2

Start: 2010-02-24End: 2011-01-20Updated: 2018-09-13

Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)

CompletedNCT01096667

Merck Sharp & Dohme LLCDiabetes Mellitus, Type 2, Hypertension

Start: 2010-05-17End: 2011-02-25Updated: 2018-09-13

Phase 3

A Study of the Efficacy and Safety of Ertugliflozin Monotherapy in the Treatment of Participants With Type 2 Diabetes Mellitus and Inadequate Glycemic Control Despite Diet and Exercise (MK-8835-003, VERTIS MONO)

CompletedNCT01958671

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-10-09End: 2016-07-28Updated: 2017-09-29

A Study of the Efficacy and Safety of Ertugliflozin in Participants With Type 2 Diabetes Mellitus With Stage 3 Chronic Kidney Disease Who Have Inadequate Glycemic Control on Antihyperglycemic Therapy (MK-8835-001)

CompletedNCT01986855

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-12-02End: 2016-09-28Updated: 2018-09-10

Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

CompletedNCT01999218

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-12-16End: 2017-04-18Updated: 2019-04-02

A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).

CompletedNCT02033889

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2013-12-13End: 2017-08-03Updated: 2018-09-10

Safety and Efficacy of Ertugliflozin in the Treatment of Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin and Sitagliptin (MK-8835-006; VERTIS SITA2)

CompletedNCT02036515

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2014-03-12End: 2016-06-06Updated: 2018-09-13

Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)

CompletedNCT02099110

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2014-04-22End: 2016-05-26Updated: 2018-09-12

A Study to Evaluate the Efficacy and Safety of Ertugliflozin in Asian Participants With Type 2 Diabetes and Inadequate Glycemic Control on Metformin Monotherapy (MK-8835-012)

CompletedNCT02630706

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2015-12-16End: 2017-12-27Updated: 2018-12-07

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

CompletedNCT04029480

Merck Sharp & Dohme LLCType 2 Diabetes Mellitus

Start: 2019-10-08End: 2025-04-11Updated: 2025-10-31

Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study

TerminatedNCT04600921

Medical University of GrazCardiac Resynchronization Therapy, Heart Failure With Mid Range Ejection Fraction, Heart Failure With Reduced Ejection Fraction +1

Start: 2021-06-24End: 2023-10-18Updated: 2025-06-03

Phase 4

Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

TerminatedNCT04071626

University Hospitals Cleveland Medical CenterDiabetes Mellitus, Type 2, Heart Failure, Diastolic

Start: 2020-03-01End: 2023-01-11Updated: 2023-12-13

Related Papers

Ertugliflozin to Reduce Arrhythmic Burden in Patients with ICDs/CRT-Ds

NEJM Evidence2024-09-0112 citations

Efficacy and Safety of Ertugliflozin Added to Metformin: A Pooled Population from Asia with Type 2 Diabetes and Overweight or Obesity

Diabetes Therapy2023-02-012 citations

Ertugliflozin to reduce arrhythmic burden in ICD/CRT patients (ERASe-trial) – A phase III study

American Heart Journal2022-01-1632 citations

Ertugliflozin + metformin as a treatment option for type 2 diabetes

Expert Opinion on Pharmacotherapy2021-06-164 citations

The effects of ertugliflozin on β‐cell function: Pooled analysis from four phase 3 randomized controlled studies

Diabetes Obesity and Metabolism2020-07-236 citations

Effects of Ertugliflozin on Liver Enzymes in Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis of Phase 3 Trials

Diabetes Therapy2020-07-0914 citations

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials.

2020-05-0518 citations

Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-2310 citations

Efficacy and safety of ertugliflozin in Hispanic/Latino patients with type 2 diabetes mellitus

Current Medical Research and Opinion2020-04-233 citations

Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials

Diabetologia2020-03-3140 citations

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus.

2020-01-039 citations

Efficacy of ertugliflozin in monotherapy or combination therapy in patients with type 2 diabetes: A pooled analysis of placebo-controlled studies

Diabetes and Vascular Disease Research2019-05-1325 citations

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials

Cardiovascular Diabetology2019-05-0720 citations

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia

Diabetes Obesity and Metabolism2019-03-0449 citations

Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin

Current Medical Research and Opinion2019-02-1450 citations

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial

Diabetes Obesity and Metabolism2019-01-0863 citations

A Pooled Analysis of the Efficacy and Safety of Ertugliflozin as Add-On Therapy to Metformin

Diabetes2018-06-223 citations

Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.

2018-02-2363 citations

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial.

2018-01-25118 citations

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study

Diabetes Therapy2017-12-27106 citations

3 more papers not shown